AMPLITUDE-O

What is AMPLITUDE-O?

Cardiovascular outcomes for efpeglenatide in type 2 diabetes at high CV risk (Gerstein et al., NEJM 2021): a 27% relative reduction in three-point MACE.

The drug was never marketed in the US, so a successful trial did not by itself make it available.

Related reading: AMPLITUDE-O: A Positive Trial for a Drug Nobody Can Buy

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.

Where AMPLITUDE-O comes up on this site

Other terms under trial

• SURMOUNT-5
• SURMOUNT-2
• SURMOUNT-3
• SURPASS-2
• SUSTAIN-6
• REWIND
• PIONEER 6
• STEP-HFpEF
• EXSCEL
• ELIXA
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SUMMIT
• SCALE Maintenance

Where the evidence lives

• The full GLP-1 glossary (150 terms, 8 categories)
• Research articles — written from primary sources
• Tools and calculators
• Compare GLP-1 telehealth providers